Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Gynecologic Cancers

9 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    Bladder
    Urologic
    Uterine

    VICCURO16119

    02/21/2018

    A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial Cancer

    Treatment

    Bladder
    Kidney (Renal Cell)
    Uterine

    VICCURO16158

    09/07/2017

    A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (ANTI−PD-L1 Antibody) as Monotherapy and in Combination with Platinum-Based Chemotherapy in Patients with Untreated Locally Advanced or Metastatic Urothelial Carcinoma

    Treatment

    Cervical

    VICCGYN16105

    06/26/2017

    Phase III Study of ADXS11-001 Administered Following Chemoradiation As Adjuvant Treatment For High Risk Locally Advanced Cervical Cancer

    Treatment

    Ovarian

    VICCGYN16132

    06/06/2017

    PiSARRO: p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin/Pegylated Liposomal Doxorubicin Combination Chemotherapy With or Without APR-246

    Treatment

    Endocrine
    Lung
    Non Small Cell
    Ovarian

    VICCTHO1722

    05/26/2017

    Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Ovarian
    Uterine

    VICCPHI1676

    11/04/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01949 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Kidney (Renal Cell)
    Lung
    Melanoma
    Miscellaneous
    Non Small Cell
    Uterine

    VICCPHI1634

    08/30/2016

    A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects with Advanced or Metastatic Solid Tumors

    Treatment

    Colon
    Head/Neck
    Lung
    Lymphoma
    Melanoma
    Non Small Cell
    Ovarian
    Rectal

    VICCPHI1531

    03/01/2016

    A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers

    Treatment

    Bladder
    Colon
    Esophageal
    Gastric/Gastroesophageal
    Neuro-Oncology
    Ovarian
    Urologic
    Uterine

    VICCMD1403

    06/02/2014

    An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification


    Print this page for your doctor